NASDAQ:ARAY Accuray Q1 2026 Earnings Report $0.33 -0.01 (-4.03%) As of 12:01 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Accuray EPS ResultsActual EPS-$0.18Consensus EPS -$0.05Beat/MissMissed by -$0.13One Year Ago EPSN/AAccuray Revenue ResultsActual Revenue$93.94 millionExpected Revenue$91.34 millionBeat/MissBeat by +$2.61 millionYoY Revenue GrowthN/AAccuray Announcement DetailsQuarterQ1 2026Date11/5/2025TimeAfter Market ClosesConference Call DateWednesday, November 5, 2025Conference Call Time4:30PM ETConference Call ResourcesConference Call AudioConference Call TranscriptSlide DeckPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfileSlide DeckFull Screen Slide DeckPowered by Accuray Q1 2026 Earnings Call TranscriptProvided by QuartrNovember 5, 2025 ShareLink copied to clipboard.Key Takeaways Positive Sentiment: New CEO and transformation plan: Steve Leneve has started as CEO and launched a transformation program (with Board sponsor Stephen Mayer) targeting a high-single-digit adjusted EBITDA margin run-rate within 12 months and double-digit margins over the medium‑to‑long term. Negative Sentiment: Quarterly results were weaker than last year: net revenue was $94.0M, down 7% YoY, with product revenue down 23% (notably softer in EIMEA and China) and product/order timing below expectations. Positive Sentiment: Recurring service business remains a bright spot: service revenue was $57.0M, up 7% YoY, with contract revenue up 10%, reflecting pricing gains and installed‑base growth that support higher-margin revenue. Negative Sentiment: Margins and profitability were pressured: overall gross margin fell to 28.3% from 33.9% (product gross margin 20.3%), driven by sales mix, ~$1.1M of tariff costs and a $0.7M obsolescence charge, contributing to an adjusted EBITDA loss of $4.1M and an operating loss of $11.3M. Positive Sentiment: Backlog and liquidity provide near‑term visibility: order backlog was ~ $396.0M (over 18 months of product revenue), book‑to‑bill ~1.1, and cash rose to $64.0M, though management expects some product demand to shift from H1 into H2. AI Generated. May Contain Errors.Conference Call Audio Live Call not available Earnings Conference CallAccuray Q1 202600:00 / 00:00Speed:1x1.25x1.5x2xTranscript SectionsPresentationParticipantsPresentationSkip to Participants Operator00:00:00Good day, and welcome to the Accuray First Quarter Fiscal 2026 Financial Results Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on a touch-tone phone. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Stephen Monroe, Vice President of Corporate Financial Planning and Analysis. Please go ahead. Stephen MonroeVP of Corporate Financial Planning and Analysis at Accuray00:00:41Thank you, and good afternoon, everyone. Welcome to Accuray's conference call to review financial results for the first quarter of fiscal year 2026, which ends September 30, 2025. During our call this afternoon, management will review recent corporate developments. Joining us on today's call are Steve La Neve, Accuray's President and Chief Executive Officer, and Ali Pervaiz, Accuray's Chief Financial Officer. Before we begin, I would like to remind you that our call today includes forward-looking statements. Actual results may differ materially from those contemplated or implied by these forward-looking statements. Factors that could cause these results to differ materially are outlined in the press release we just issued after the market closed this afternoon, as well as in our filings with the Securities and Exchange Commission. We base the forward-looking statements on this call on the information available to us as of today's date. Stephen MonroeVP of Corporate Financial Planning and Analysis at Accuray00:01:40We assume no obligation to update any forward-looking statements as a result of new information or future events, except to the extent required by applicable securities laws. Accordingly, you should not put undue reliance on any forward-looking statements. A few housekeeping items for today's call. All references to a specific quarter in the prepared remarks are to our fiscal year quarters. For example, statements regarding our first quarter refer to our fiscal first quarter ending September 30, 2025. Additionally, there will be a supplemental slide deck to accompany this call, which you can access by going directly to Accuray's Investor Relations page at investors.accuray.com. With that, let me turn the call over to Accuray's Chief Executive Officer, Steve La Neve. Steve? Steve La NevePresident and CEO at Accuray00:02:33Thank you, Steve. Good afternoon, everyone, and thank you for joining us today. It's a privilege to address you on my first earnings call as Accuray's CEO. I want to begin by recognizing the remarkable dedication and expertise of the entire Accuray team, whose commitment and innovative technologies have made a meaningful difference in patients' lives around the world. I have also genuinely appreciated the transition time that Suzanne is making for me as I onboard. Today, I'm excited to share why I chose to join Accuray and my high level of conviction in Accuray's success as we enter the next phase of transformational growth. Accuray is one of just a few companies operating at the intersection of technical sophistication and human impact. Steve La NevePresident and CEO at Accuray00:03:23I have a tremendous amount of respect for what the Accuray radiation delivery systems can do to prolong life and for being indispensable in treating Malignant and Non-Malignant disease. I've spent my first several weeks at the company listening to and learning from many different stakeholders, and I continue to be incredibly impressed with Accuray's foundation and technology. This makes me more confident than ever about the potential to enhance our performance, market position, and our long-term growth prospects. Here's why I have this belief. I've come to Accuray with over 40 years of global experience in Medtech and Biotech, including capital equipment. I've held executive leadership and CEO roles at high-performing, well-differentiated, and impactful publicly traded companies, including Roche Diagnostics, Becton Dickinson, Medtronic, Etext, Bowden Biologics Corporation, and most recently at Globus Medical. Steve La NevePresident and CEO at Accuray00:04:24The common thread across my experience was driving top-line growth profitably while meaningfully improving patients' lives with innovative technology. This was achieved by creating clear strategic and financial goals, solid execution against these goals, consistently identifying avenues to optimize operations and grow margins, and disciplined cost management. I am encouraged by what I've seen so far at Accuray, and I'm even more optimistic about the tremendous opportunities ahead. This is where our transformation plan comes in. Our immediate goal is to identify key strategic, operational, and financial areas that we believe are necessary to position Accuray to compete more effectively, drive margin expansion, enhance organizational responsiveness and agility, and ultimately position Accuray for sustainable, profitable growth. In short, continue to build a performance-based culture. Steve La NevePresident and CEO at Accuray00:05:25As mentioned in our news release a couple of weeks ago, Steven Mayer, one of Accuray's board members and our transformation board sponsor, will support us with this set of initiatives. Steven brings extensive experience leading complex corporate transformations and will be instrumental in helping us to prioritize our resources, sharpen our focus, and reinforce our culture of continuous improvement. The management team and I look forward to working closely with Steven to execute on these goals. In the near term, as we implement key changes during the current fiscal year, we expect to reach a high single-digit adjusted EBITDA margin as a percentage of revenue on a run-rate basis within 12 months. Steve La NevePresident and CEO at Accuray00:06:12Furthermore, we are confident that our transformation efforts will enable us to expand our adjusted EBITDA margin as a percentage of revenue to double digits over the medium to long term and drive sustained and profitable growth for our company. We look forward to presenting more details on our transformation plan in early 2026. We will be updating you on the progress being made toward our goals on a regular cadence. I will now turn the call over to Ali to review the first quarter results. Ali? Ali PervaizCFO at Accuray00:06:45Thanks, Steve, and welcome to the Accuray team. We look forward to working closely with you as we execute on our transformation plan. Before discussing our financial highlights, I wanted to call out some major wins during the quarter. In September, we launched our Stellar product at Astro. This was more than a product debut. It was a statement. Stellar represents our commitment to adaptive radiotherapy and our belief that every patient deserves precision care. The reception at Astro was overwhelmingly positive, and we're already seeing strong interest from both existing and new customers. This is the kind of innovation that sets Accuray apart. Other highlights in the quarter include the announced signing of a memorandum of understanding with the University of Wisconsin School of Medicine and Public Health to Advance Online Adaptive Radiotherapy on the Accuray Helical Radiation Treatment Delivery Platform. Ali PervaizCFO at Accuray00:07:38As part of the MOU, the two parties outlined their intent to collaborate on clinical research, education and training, and adaptive technology development to help empower medical care teams to raise the bar in the personalization and precision of cancer care. Another highlight was the announcement of first patients treated in Melbourne, Australia, using our CyberKnife system. Aligned with the Accuray mission to expand the curative power of radiation therapy, the recent treatment using a CyberKnife system fills an unmet cancer need in Australia to improve community access to this powerful technology while limiting the patient's need to travel long distances for care. Both these events provide further testament to the high level of interest in adoption of our technology, both in the U.S. as well as globally. Ali PervaizCFO at Accuray00:08:27Turning to the first quarter results, net revenue for the first quarter was $94 million, which was down 7% versus the prior year and down 9% on a constant currency basis. As you know, due to the long sales cycle and relatively low unit volumes in the product side of our business, quarterly product revenues can be volatile. With that said, product revenue for the first quarter was $37 million, which was below expectations, mainly due to slower performance in our EMEA and China regions. Year-over-year product revenue was down 23% and down 24% on a constant currency basis. On the other hand, as you know, our install base generates a relatively predictable, higher-margin, valuable revenue stream, which continues to grow and which we intend to emphasize strategically. Ali PervaizCFO at Accuray00:09:15Service revenue was, again, the highlight of the quarter, with revenue of $57 million, up 7% from the prior year and up 4% on a constant currency basis. This increase was driven by contract revenue growth of 10% year-over-year, which was higher than our installed rates growth of 2% over the same period, illustrating that our pricing actions are taking effect. Product orders for the first quarter were approximately $40 million and represented a book-to-bill ratio of 1.1, with a trailing 12-month ratio of 1.2. Gross orders were also lower than our expectations for the first quarter, which was largely due to timing of receipt of customer orders for certain projects in China and the Americas regions. We ended the first quarter with a reporting order backlog of approximately $396 million. Defined as orders that are younger than 30 months. Ali PervaizCFO at Accuray00:10:04This represents over 18 months of product revenue, giving us strong visibility and confidence in future revenue conversion. As part of our diligence in ensuring a high-quality backlog, we canceled one unit representing approximately $2 million of orders to maintain a high-quality backlog. Our overall gross margin for the quarter was 28.3% compared to 33.9% in the prior year. This decline was primarily driven by product gross margins, which were 20.3% compared to 32.9% in the prior year. The key elements that unfavorably impacted product gross margins were sales mix, both geographical and by product, of $2.9 million, or 7.8 points. Incremental costs associated with the tariffs announced earlier this year of $1.1 million, or 3 points, and a one-time obsolescence charge associated with aged inventory of $0.7 million, or 1.7 points. Ali PervaizCFO at Accuray00:11:02Service gross margins were 33.5%, 1.4 points lower than the prior year, primarily driven by lower parts consumption in Q1 of fiscal year 2025 due to a supplier credit obtained in that quarter. Overall, we continue to be focused on margin expansion in our service. That is driven by higher pricing and reducing our cost to serve. Operating expenses in the first quarter of $37.9 million compared to $36.6 million in the first quarter of the prior fiscal year. The increase was largely due to $3.3 million in restructuring and post-financing costs recorded within operating expenses this quarter. This was partially offset with $1 million in realized savings from restructuring actions. Operating loss for the quarter was $11.3 million compared to a loss of $2.1 million from the prior year. During the first quarter of fiscal 2026, we also had some one-time items that impacted financial results during this period. Ali PervaizCFO at Accuray00:11:58The company initiated a restructuring plan aimed at reducing costs, aligning resources with strategic priorities, and streamlining operations. This resulted in $2.8 million in restructuring charges, which included $1.5 million in service-related costs and $1.3 million in consulting costs directly related to the restructuring plan. Adjusted EBITDA for the quarter was a loss of $4.1 million compared to an income of $3.1 million in the prior year. This was largely due to the product gross margin challenges discussed earlier. We described the reconciliation between GAAP net income and adjusted EBITDA in our earnings release issued today. Turning to the balance sheet, total cash, cash equivalents, and short-term restricted cash amounted to $64 million compared to $57 million at the end of last quarter, primarily due to the net decrease in primary working capital. Ali PervaizCFO at Accuray00:12:53Net accounts receivable were $54 million, down $29 million from the prior quarter due to lower revenues and collection of certain past year receivables. Our net inventory balance was $156 million, up $14 million from the prior quarter as we ramp up for increased manufacturing in the coming quarters. Turning to guidance, although we have had a slower than anticipated start for the first fiscal quarter of fiscal year 2026, we have confidence in our cross-functional teams to execute the plan we have set out in the beginning of the fiscal year. With that in mind, we are reiterating our fiscal year 2026 guidance with revenue in the range of $471 million-$485 million and an adjusted EBITDA range of $31 million-$35 million. Ali PervaizCFO at Accuray00:13:38We plan to provide more details behind the new transformation plan, which is expected to meaningfully improve our adjusted EBITDA as a percentage of revenue on our fiscal Q2 earnings call. With that, I'd like to hand the call back to Steve. Steve La NevePresident and CEO at Accuray00:13:52Thank you, Ali. At this point, as Ali indicated, guidance is unchanged. However, in the next 90 days, I will have a better feel for the organization, the progress of the transformation initiative, and the external market dynamics in order to make an assessment of revenue and adjusted EBITDA guidance for the fiscal year at that time. As I begin my tenure, I see the path to deliver the adjusted EBITDA guidance with increased earnings momentum going into FY 2027, even with the ongoing geopolitical and macroeconomic uncertainties. In closing, I'm extremely excited to have joined Accuray at this critical time of transformation for the company. My underlying goal is to foster a performance-driven culture that pairs innovation with execution, strengthens operational discipline, and drives sustainable, profitable growth while creating long-term value for the patients, providers, and shareholders we serve. Steve La NevePresident and CEO at Accuray00:14:49I will now turn it back over to the operator for Q&A. Operator00:14:58We will now begin the question and answer session. To ask a question, you may press star then one on your touch tone phone. If you are using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw the question, please press star then two. At this time, we will pause momentarily to assemble our roster. Our first question comes from Marie Thibault from BTIG. Please go ahead. Marie ThibaultManaging Director at BTIG00:15:39Good afternoon. Thank you for taking the questions. Hi, Ali, and nice to be working with you, Steve. Welcome. Wanted to start here on sort of a high level and understand what you're seeing out there in terms of the capital equipment purchasing environment, the ordering environment. You did talk a little bit about product revenue and some of the recognition, of course, but wanted to understand if you're seeing things get better, get worse, stabilize in the various regions on the ordering front. Ali PervaizCFO at Accuray00:16:10Yeah, hi, Marie. Thanks so much for the question. That answer really varies by region. Obviously, this particular quarter, we did see a slowdown in EMEA and in China, mainly due to some of the geopolitical and macro issues that we are starting to see ease up a little bit. The U.S., we feel okay about from an overall capital equipment standpoint. I mean, we continue to see growth in our APAC business. It really does vary by region. I think overall, we're still going to continue to work with our region teams to gain a better pulse in terms of how capital equipment is shaping up as we look into the rest of fiscal year 2026. Marie ThibaultManaging Director at BTIG00:17:01Okay, that's very helpful, Ali. As part of that, I also wanted to ask on net orders. Certainly a bigger difference between gross orders and net orders than we're used to seeing this quarter. Did some of that have to do? I heard about the cancellation, but did some of that have to do with age outs, maybe related to China? Just any detail on that? Ali PervaizCFO at Accuray00:17:21We did have age outs, but I would say they weren't out of the norm, Marie. At the end of the day, I tend to focus more on gross orders because that truly is a representation of new business that's coming in. We reported new gross orders from across the globe of about $40 million, which was lower than expectation and primarily related to timing of customer receipts in both the Americas and in China. Marie ThibaultManaging Director at BTIG00:17:47Okay. If I may sneak in one other, just wanted to hear the latest on kind of tariff mitigation efforts. I know that you have a number of initiatives to sort of offset some of that. Any progress or any updates on those? Ali PervaizCFO at Accuray00:18:01Yeah, you know we continue to take a look at the duty drawback program, which is something that will allow us to at least regain tariffs that we've paid on any equipment that does not remain in the U.S. That is a program that is very active for us. We have in the past sort of spoken about implementation of a foreign trade zone, which is certainly something that we continue to take a look at to see, does that make sense for us? As this tariff environment is pretty fluid, that is certainly something that is on the table as well. It certainly is a pretty fluid situation, Marie, as you know, the headlines change quite frequently, but we keep a pretty close pulse on it. I think that's sort of what's happening from a tariff standpoint. Ali PervaizCFO at Accuray00:18:53Marie, I will take the opportunity because I know we did reiterate guidance this particular earnings call as well. I think it's important to highlight that we're really pleased with the continued growth in our service business, and we expect that to continue through the year. Product revenue was obviously slower than anticipated in Q1 due to what I was highlighting in the prepared remarks in terms of slower performance in EMEA and China. We do expect that to continue in the second quarter. With geopolitical macro issues starting to ease, we're confident that a lot of the orders that we will not deliver in the first half will actually shift into the second half based upon customer schedules and feedback that we've gotten from our teams on the ground, as well as our JV partner in China. Ali PervaizCFO at Accuray00:19:40With that, I think it's really important to highlight that we do expect first half revenue to be closer to about 40% of our full year guidance and then second half to be about 60% of our full year guidance because we are seeing some of this product demand shift to the second half. Obviously, we're going to keep a close pulse on it to see if there's any other dynamics that happen from each of the different regions, but this is what we're seeing right now. Marie ThibaultManaging Director at BTIG00:20:05Hey, that's really helpful, Ali, and I appreciate that, especially the 40-60 split. We'll make note of that. I know in the past it's been 45-55, so certainly helpful to have that split now. If I could then maybe follow up with one more question just on the margin side. I heard the commentary about product and geography mix impacting product gross margins. It sounds like that should also continue into fiscal second quarter and then possibly improve in the second half. Is that the right way to think about that as well, Ali? Ali PervaizCFO at Accuray00:20:37I think that's the right way to think about it, Marie. We did have more deals that went into emerging markets that contributed to revenue in Q1. We expect something similar in Q2. As we start to execute in our backlog that has more that's teed up for developed markets, those come with a better margin profile. I think at the end of the day, Marie, we've spoken about this in the past, in which really we just want to be able to continue to make sure that we're getting our install base to increase, and that's really going to help our service business grow. You saw that as a highlight in terms of service grew by about 7% this quarter and contract revenue grew by about 10%. Ali PervaizCFO at Accuray00:21:20I feel really good about the way that our service business is positioned right now and moving forward. Marie ThibaultManaging Director at BTIG00:21:26Okay, very helpful. I'll jump back in queue. Thank you. Ali PervaizCFO at Accuray00:21:29Thank you, Marie. Operator00:21:34Again, if you have a question, please press star then one. Operator00:21:56At this time, there are no more questions. This concludes our question and answer session. I would like to turn the conference back over to Steve La Neve, President and CEO, for any closing remarks. Steve La NevePresident and CEO at Accuray00:22:09Thank you all for joining our call today, and we look forward to speaking with you again in February when we report our fiscal 2026 second quarter earnings results. This concludes our earnings call. Thank you. Operator00:22:27The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.Read moreParticipantsExecutivesStephen MonroeVP of Corporate Financial Planning and AnalysisAli PervaizCFOSteve La NevePresident and CEOAnalystsMarie ThibaultManaging Director at BTIGPowered by Earnings DocumentsSlide DeckEarnings Release(8-K)Quarterly Report(10-Q) Accuray Earnings HeadlinesAccuray Slides As Insider Purchases Lose Another US$95kMay 11 at 7:44 AM | finance.yahoo.comAccuray withdraws guidance amid Middle East disruptions while targeting $25M annualized profitability improvement in fiscal 2027May 8, 2026 | seekingalpha.comIran broke the petrodollar…For 50 years, every barrel of oil settled in dollars - that rule is what made the dollar the world's reserve currency. Iran just broke it, and no sanctions can restore the status quo. Garrett Goggin, CFA, CMT has guided readers to gains of 1,200% over the last two years by tracking gold's rise against a weakening dollar. He's identified four miners positioned to profit through what he calls the last gold bull market of our lifetime.May 12 at 1:00 AM | Golden Portfolio (Ad)BTIG downgrades Accuray (ARAY)May 8, 2026 | msn.comAccuray Faces Nasdaq Delisting Risk as Shares Fall Below $1 Minimum Bid PriceMay 8, 2026 | tipranks.comAccuray (ARAY) Q3 2026 Earnings TranscriptMay 7, 2026 | finance.yahoo.comSee More Accuray Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Accuray? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Accuray and other key companies, straight to your email. Email Address About AccurayAccuray (NASDAQ:ARAY) (NASDAQ: ARAY) is a global medical device company that develops, manufactures and markets innovative radiation therapy solutions for the treatment of cancer. The company’s flagship products include the CyberKnife® System, a robotic radiosurgery platform offering sub-millimeter precision, and the TomoTherapy® System, which combines helical computed tomography (CT) imaging with intensity-modulated radiation therapy (IMRT). More recently, Accuray introduced the Radixact® System, an advanced iteration of its TomoTherapy technology designed to enhance treatment speed and clinical workflow. Accuray’s suite of products enables clinicians to deliver highly targeted radiation doses while minimizing exposure to surrounding healthy tissue. The CyberKnife platform is widely used for stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT), supporting treatments across a range of tumor types and anatomical sites. The TomoTherapy and Radixact systems incorporate integrated imaging, adaptive planning and dose-shaping capabilities that support daily adjustments in treatment delivery, helping to improve patient outcomes and operational efficiency in oncology centers. Founded in 1990 and headquartered in Madison, Wisconsin, Accuray serves a broad network of hospitals, cancer centers and research institutions in North America, Europe, Asia-Pacific and other regions. The company maintains additional offices and service centers in locations such as Sunnyvale, California; Milan, Italy; and Singapore to support its global customer base. Since September 2017, Accuray has been led by President and Chief Executive Officer Peter C. Arduini, whose background in medical technology and healthcare operations has guided the company’s focus on product innovation and clinical collaboration.View Accuray ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles On Holdings Sets Up for Marathon Rally: New Highs Are ComingMP Materials Is Quietly Building a Rare Earth PowerhouseUbiquiti’s Uptrend Can Continue, But Don’t Rush to Buy ItAI Demand Fuels Strong Q1 Earnings for Constellation EnergyMercadoLibre Boldly Invests in Growth: Discount DeepensManic Monday.com: The Rally Is Just the Beginning for this SaaS LeaderMeta Platforms’ Wild Post-Earnings Swings: Where Analyst Price Targets Stand Now Upcoming Earnings Cisco Systems (5/13/2026)Alibaba Group (5/13/2026)Manulife Financial (5/13/2026)Sumitomo Mitsui Financial Group (5/13/2026)Takeda Pharmaceutical (5/13/2026)Applied Materials (5/14/2026)Brookfield (5/14/2026)National Grid Transco (5/14/2026)NU (5/14/2026)Mizuho Financial Group (5/15/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PresentationSkip to Participants Operator00:00:00Good day, and welcome to the Accuray First Quarter Fiscal 2026 Financial Results Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on a touch-tone phone. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Stephen Monroe, Vice President of Corporate Financial Planning and Analysis. Please go ahead. Stephen MonroeVP of Corporate Financial Planning and Analysis at Accuray00:00:41Thank you, and good afternoon, everyone. Welcome to Accuray's conference call to review financial results for the first quarter of fiscal year 2026, which ends September 30, 2025. During our call this afternoon, management will review recent corporate developments. Joining us on today's call are Steve La Neve, Accuray's President and Chief Executive Officer, and Ali Pervaiz, Accuray's Chief Financial Officer. Before we begin, I would like to remind you that our call today includes forward-looking statements. Actual results may differ materially from those contemplated or implied by these forward-looking statements. Factors that could cause these results to differ materially are outlined in the press release we just issued after the market closed this afternoon, as well as in our filings with the Securities and Exchange Commission. We base the forward-looking statements on this call on the information available to us as of today's date. Stephen MonroeVP of Corporate Financial Planning and Analysis at Accuray00:01:40We assume no obligation to update any forward-looking statements as a result of new information or future events, except to the extent required by applicable securities laws. Accordingly, you should not put undue reliance on any forward-looking statements. A few housekeeping items for today's call. All references to a specific quarter in the prepared remarks are to our fiscal year quarters. For example, statements regarding our first quarter refer to our fiscal first quarter ending September 30, 2025. Additionally, there will be a supplemental slide deck to accompany this call, which you can access by going directly to Accuray's Investor Relations page at investors.accuray.com. With that, let me turn the call over to Accuray's Chief Executive Officer, Steve La Neve. Steve? Steve La NevePresident and CEO at Accuray00:02:33Thank you, Steve. Good afternoon, everyone, and thank you for joining us today. It's a privilege to address you on my first earnings call as Accuray's CEO. I want to begin by recognizing the remarkable dedication and expertise of the entire Accuray team, whose commitment and innovative technologies have made a meaningful difference in patients' lives around the world. I have also genuinely appreciated the transition time that Suzanne is making for me as I onboard. Today, I'm excited to share why I chose to join Accuray and my high level of conviction in Accuray's success as we enter the next phase of transformational growth. Accuray is one of just a few companies operating at the intersection of technical sophistication and human impact. Steve La NevePresident and CEO at Accuray00:03:23I have a tremendous amount of respect for what the Accuray radiation delivery systems can do to prolong life and for being indispensable in treating Malignant and Non-Malignant disease. I've spent my first several weeks at the company listening to and learning from many different stakeholders, and I continue to be incredibly impressed with Accuray's foundation and technology. This makes me more confident than ever about the potential to enhance our performance, market position, and our long-term growth prospects. Here's why I have this belief. I've come to Accuray with over 40 years of global experience in Medtech and Biotech, including capital equipment. I've held executive leadership and CEO roles at high-performing, well-differentiated, and impactful publicly traded companies, including Roche Diagnostics, Becton Dickinson, Medtronic, Etext, Bowden Biologics Corporation, and most recently at Globus Medical. Steve La NevePresident and CEO at Accuray00:04:24The common thread across my experience was driving top-line growth profitably while meaningfully improving patients' lives with innovative technology. This was achieved by creating clear strategic and financial goals, solid execution against these goals, consistently identifying avenues to optimize operations and grow margins, and disciplined cost management. I am encouraged by what I've seen so far at Accuray, and I'm even more optimistic about the tremendous opportunities ahead. This is where our transformation plan comes in. Our immediate goal is to identify key strategic, operational, and financial areas that we believe are necessary to position Accuray to compete more effectively, drive margin expansion, enhance organizational responsiveness and agility, and ultimately position Accuray for sustainable, profitable growth. In short, continue to build a performance-based culture. Steve La NevePresident and CEO at Accuray00:05:25As mentioned in our news release a couple of weeks ago, Steven Mayer, one of Accuray's board members and our transformation board sponsor, will support us with this set of initiatives. Steven brings extensive experience leading complex corporate transformations and will be instrumental in helping us to prioritize our resources, sharpen our focus, and reinforce our culture of continuous improvement. The management team and I look forward to working closely with Steven to execute on these goals. In the near term, as we implement key changes during the current fiscal year, we expect to reach a high single-digit adjusted EBITDA margin as a percentage of revenue on a run-rate basis within 12 months. Steve La NevePresident and CEO at Accuray00:06:12Furthermore, we are confident that our transformation efforts will enable us to expand our adjusted EBITDA margin as a percentage of revenue to double digits over the medium to long term and drive sustained and profitable growth for our company. We look forward to presenting more details on our transformation plan in early 2026. We will be updating you on the progress being made toward our goals on a regular cadence. I will now turn the call over to Ali to review the first quarter results. Ali? Ali PervaizCFO at Accuray00:06:45Thanks, Steve, and welcome to the Accuray team. We look forward to working closely with you as we execute on our transformation plan. Before discussing our financial highlights, I wanted to call out some major wins during the quarter. In September, we launched our Stellar product at Astro. This was more than a product debut. It was a statement. Stellar represents our commitment to adaptive radiotherapy and our belief that every patient deserves precision care. The reception at Astro was overwhelmingly positive, and we're already seeing strong interest from both existing and new customers. This is the kind of innovation that sets Accuray apart. Other highlights in the quarter include the announced signing of a memorandum of understanding with the University of Wisconsin School of Medicine and Public Health to Advance Online Adaptive Radiotherapy on the Accuray Helical Radiation Treatment Delivery Platform. Ali PervaizCFO at Accuray00:07:38As part of the MOU, the two parties outlined their intent to collaborate on clinical research, education and training, and adaptive technology development to help empower medical care teams to raise the bar in the personalization and precision of cancer care. Another highlight was the announcement of first patients treated in Melbourne, Australia, using our CyberKnife system. Aligned with the Accuray mission to expand the curative power of radiation therapy, the recent treatment using a CyberKnife system fills an unmet cancer need in Australia to improve community access to this powerful technology while limiting the patient's need to travel long distances for care. Both these events provide further testament to the high level of interest in adoption of our technology, both in the U.S. as well as globally. Ali PervaizCFO at Accuray00:08:27Turning to the first quarter results, net revenue for the first quarter was $94 million, which was down 7% versus the prior year and down 9% on a constant currency basis. As you know, due to the long sales cycle and relatively low unit volumes in the product side of our business, quarterly product revenues can be volatile. With that said, product revenue for the first quarter was $37 million, which was below expectations, mainly due to slower performance in our EMEA and China regions. Year-over-year product revenue was down 23% and down 24% on a constant currency basis. On the other hand, as you know, our install base generates a relatively predictable, higher-margin, valuable revenue stream, which continues to grow and which we intend to emphasize strategically. Ali PervaizCFO at Accuray00:09:15Service revenue was, again, the highlight of the quarter, with revenue of $57 million, up 7% from the prior year and up 4% on a constant currency basis. This increase was driven by contract revenue growth of 10% year-over-year, which was higher than our installed rates growth of 2% over the same period, illustrating that our pricing actions are taking effect. Product orders for the first quarter were approximately $40 million and represented a book-to-bill ratio of 1.1, with a trailing 12-month ratio of 1.2. Gross orders were also lower than our expectations for the first quarter, which was largely due to timing of receipt of customer orders for certain projects in China and the Americas regions. We ended the first quarter with a reporting order backlog of approximately $396 million. Defined as orders that are younger than 30 months. Ali PervaizCFO at Accuray00:10:04This represents over 18 months of product revenue, giving us strong visibility and confidence in future revenue conversion. As part of our diligence in ensuring a high-quality backlog, we canceled one unit representing approximately $2 million of orders to maintain a high-quality backlog. Our overall gross margin for the quarter was 28.3% compared to 33.9% in the prior year. This decline was primarily driven by product gross margins, which were 20.3% compared to 32.9% in the prior year. The key elements that unfavorably impacted product gross margins were sales mix, both geographical and by product, of $2.9 million, or 7.8 points. Incremental costs associated with the tariffs announced earlier this year of $1.1 million, or 3 points, and a one-time obsolescence charge associated with aged inventory of $0.7 million, or 1.7 points. Ali PervaizCFO at Accuray00:11:02Service gross margins were 33.5%, 1.4 points lower than the prior year, primarily driven by lower parts consumption in Q1 of fiscal year 2025 due to a supplier credit obtained in that quarter. Overall, we continue to be focused on margin expansion in our service. That is driven by higher pricing and reducing our cost to serve. Operating expenses in the first quarter of $37.9 million compared to $36.6 million in the first quarter of the prior fiscal year. The increase was largely due to $3.3 million in restructuring and post-financing costs recorded within operating expenses this quarter. This was partially offset with $1 million in realized savings from restructuring actions. Operating loss for the quarter was $11.3 million compared to a loss of $2.1 million from the prior year. During the first quarter of fiscal 2026, we also had some one-time items that impacted financial results during this period. Ali PervaizCFO at Accuray00:11:58The company initiated a restructuring plan aimed at reducing costs, aligning resources with strategic priorities, and streamlining operations. This resulted in $2.8 million in restructuring charges, which included $1.5 million in service-related costs and $1.3 million in consulting costs directly related to the restructuring plan. Adjusted EBITDA for the quarter was a loss of $4.1 million compared to an income of $3.1 million in the prior year. This was largely due to the product gross margin challenges discussed earlier. We described the reconciliation between GAAP net income and adjusted EBITDA in our earnings release issued today. Turning to the balance sheet, total cash, cash equivalents, and short-term restricted cash amounted to $64 million compared to $57 million at the end of last quarter, primarily due to the net decrease in primary working capital. Ali PervaizCFO at Accuray00:12:53Net accounts receivable were $54 million, down $29 million from the prior quarter due to lower revenues and collection of certain past year receivables. Our net inventory balance was $156 million, up $14 million from the prior quarter as we ramp up for increased manufacturing in the coming quarters. Turning to guidance, although we have had a slower than anticipated start for the first fiscal quarter of fiscal year 2026, we have confidence in our cross-functional teams to execute the plan we have set out in the beginning of the fiscal year. With that in mind, we are reiterating our fiscal year 2026 guidance with revenue in the range of $471 million-$485 million and an adjusted EBITDA range of $31 million-$35 million. Ali PervaizCFO at Accuray00:13:38We plan to provide more details behind the new transformation plan, which is expected to meaningfully improve our adjusted EBITDA as a percentage of revenue on our fiscal Q2 earnings call. With that, I'd like to hand the call back to Steve. Steve La NevePresident and CEO at Accuray00:13:52Thank you, Ali. At this point, as Ali indicated, guidance is unchanged. However, in the next 90 days, I will have a better feel for the organization, the progress of the transformation initiative, and the external market dynamics in order to make an assessment of revenue and adjusted EBITDA guidance for the fiscal year at that time. As I begin my tenure, I see the path to deliver the adjusted EBITDA guidance with increased earnings momentum going into FY 2027, even with the ongoing geopolitical and macroeconomic uncertainties. In closing, I'm extremely excited to have joined Accuray at this critical time of transformation for the company. My underlying goal is to foster a performance-driven culture that pairs innovation with execution, strengthens operational discipline, and drives sustainable, profitable growth while creating long-term value for the patients, providers, and shareholders we serve. Steve La NevePresident and CEO at Accuray00:14:49I will now turn it back over to the operator for Q&A. Operator00:14:58We will now begin the question and answer session. To ask a question, you may press star then one on your touch tone phone. If you are using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw the question, please press star then two. At this time, we will pause momentarily to assemble our roster. Our first question comes from Marie Thibault from BTIG. Please go ahead. Marie ThibaultManaging Director at BTIG00:15:39Good afternoon. Thank you for taking the questions. Hi, Ali, and nice to be working with you, Steve. Welcome. Wanted to start here on sort of a high level and understand what you're seeing out there in terms of the capital equipment purchasing environment, the ordering environment. You did talk a little bit about product revenue and some of the recognition, of course, but wanted to understand if you're seeing things get better, get worse, stabilize in the various regions on the ordering front. Ali PervaizCFO at Accuray00:16:10Yeah, hi, Marie. Thanks so much for the question. That answer really varies by region. Obviously, this particular quarter, we did see a slowdown in EMEA and in China, mainly due to some of the geopolitical and macro issues that we are starting to see ease up a little bit. The U.S., we feel okay about from an overall capital equipment standpoint. I mean, we continue to see growth in our APAC business. It really does vary by region. I think overall, we're still going to continue to work with our region teams to gain a better pulse in terms of how capital equipment is shaping up as we look into the rest of fiscal year 2026. Marie ThibaultManaging Director at BTIG00:17:01Okay, that's very helpful, Ali. As part of that, I also wanted to ask on net orders. Certainly a bigger difference between gross orders and net orders than we're used to seeing this quarter. Did some of that have to do? I heard about the cancellation, but did some of that have to do with age outs, maybe related to China? Just any detail on that? Ali PervaizCFO at Accuray00:17:21We did have age outs, but I would say they weren't out of the norm, Marie. At the end of the day, I tend to focus more on gross orders because that truly is a representation of new business that's coming in. We reported new gross orders from across the globe of about $40 million, which was lower than expectation and primarily related to timing of customer receipts in both the Americas and in China. Marie ThibaultManaging Director at BTIG00:17:47Okay. If I may sneak in one other, just wanted to hear the latest on kind of tariff mitigation efforts. I know that you have a number of initiatives to sort of offset some of that. Any progress or any updates on those? Ali PervaizCFO at Accuray00:18:01Yeah, you know we continue to take a look at the duty drawback program, which is something that will allow us to at least regain tariffs that we've paid on any equipment that does not remain in the U.S. That is a program that is very active for us. We have in the past sort of spoken about implementation of a foreign trade zone, which is certainly something that we continue to take a look at to see, does that make sense for us? As this tariff environment is pretty fluid, that is certainly something that is on the table as well. It certainly is a pretty fluid situation, Marie, as you know, the headlines change quite frequently, but we keep a pretty close pulse on it. I think that's sort of what's happening from a tariff standpoint. Ali PervaizCFO at Accuray00:18:53Marie, I will take the opportunity because I know we did reiterate guidance this particular earnings call as well. I think it's important to highlight that we're really pleased with the continued growth in our service business, and we expect that to continue through the year. Product revenue was obviously slower than anticipated in Q1 due to what I was highlighting in the prepared remarks in terms of slower performance in EMEA and China. We do expect that to continue in the second quarter. With geopolitical macro issues starting to ease, we're confident that a lot of the orders that we will not deliver in the first half will actually shift into the second half based upon customer schedules and feedback that we've gotten from our teams on the ground, as well as our JV partner in China. Ali PervaizCFO at Accuray00:19:40With that, I think it's really important to highlight that we do expect first half revenue to be closer to about 40% of our full year guidance and then second half to be about 60% of our full year guidance because we are seeing some of this product demand shift to the second half. Obviously, we're going to keep a close pulse on it to see if there's any other dynamics that happen from each of the different regions, but this is what we're seeing right now. Marie ThibaultManaging Director at BTIG00:20:05Hey, that's really helpful, Ali, and I appreciate that, especially the 40-60 split. We'll make note of that. I know in the past it's been 45-55, so certainly helpful to have that split now. If I could then maybe follow up with one more question just on the margin side. I heard the commentary about product and geography mix impacting product gross margins. It sounds like that should also continue into fiscal second quarter and then possibly improve in the second half. Is that the right way to think about that as well, Ali? Ali PervaizCFO at Accuray00:20:37I think that's the right way to think about it, Marie. We did have more deals that went into emerging markets that contributed to revenue in Q1. We expect something similar in Q2. As we start to execute in our backlog that has more that's teed up for developed markets, those come with a better margin profile. I think at the end of the day, Marie, we've spoken about this in the past, in which really we just want to be able to continue to make sure that we're getting our install base to increase, and that's really going to help our service business grow. You saw that as a highlight in terms of service grew by about 7% this quarter and contract revenue grew by about 10%. Ali PervaizCFO at Accuray00:21:20I feel really good about the way that our service business is positioned right now and moving forward. Marie ThibaultManaging Director at BTIG00:21:26Okay, very helpful. I'll jump back in queue. Thank you. Ali PervaizCFO at Accuray00:21:29Thank you, Marie. Operator00:21:34Again, if you have a question, please press star then one. Operator00:21:56At this time, there are no more questions. This concludes our question and answer session. I would like to turn the conference back over to Steve La Neve, President and CEO, for any closing remarks. Steve La NevePresident and CEO at Accuray00:22:09Thank you all for joining our call today, and we look forward to speaking with you again in February when we report our fiscal 2026 second quarter earnings results. This concludes our earnings call. Thank you. Operator00:22:27The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.Read moreParticipantsExecutivesStephen MonroeVP of Corporate Financial Planning and AnalysisAli PervaizCFOSteve La NevePresident and CEOAnalystsMarie ThibaultManaging Director at BTIGPowered by